297 related articles for article (PubMed ID: 35148283)
41. An angiogenesis-related long noncoding RNA signature correlates with prognosis in patients with hepatocellular carcinoma.
Lei D; Chen Y; Zhou Y; Hu G; Luo F
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33764367
[TBL] [Abstract][Full Text] [Related]
42. An epithelial-mesenchymal transition-related long noncoding RNA signature correlates with the prognosis and progression in patients with bladder cancer.
Tong H; Li T; Gao S; Yin H; Cao H; He W
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33289830
[TBL] [Abstract][Full Text] [Related]
43. Identification of a Nine Immune-Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma.
Yuan M; Wang Y; Sun Q; Liu S; Xian S; Dai F; Zhang L; Fan Y; Wang F; Yang D; Zheng Y; Deng Z; Tan W; Liu Y; Cheng Y
Biomed Res Int; 2021; 2021():9798231. PubMed ID: 33506049
[TBL] [Abstract][Full Text] [Related]
44. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
[TBL] [Abstract][Full Text] [Related]
45. Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in Glioma.
Tao C; Luo H; Chen L; Li J; Zhu X; Huang K
Bioengineered; 2021 Dec; 12(1):4016-4031. PubMed ID: 34288803
[TBL] [Abstract][Full Text] [Related]
46. Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
Zhong Z; Xu M; Tan J
Pathol Oncol Res; 2022; 28():1610670. PubMed ID: 36277962
[No Abstract] [Full Text] [Related]
47. Identification of an immune-related 6-lncRNA panel with a good performance for prognostic prediction in hepatocellular carcinoma by integrated bioinformatics analysis.
Lu S; Liu X; Wu C; Zhang J; Stalin A; Huang Z; Tan Y; Wu Z; You L; Ye P; Fu C; Zhang X; Wu J
Medicine (Baltimore); 2023 Jul; 102(29):e33990. PubMed ID: 37478241
[TBL] [Abstract][Full Text] [Related]
48. Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma.
Wang X; Qian J; Yao N; Pocha C; Kang KJ; Angelico R; Zhu G
Ann Transl Med; 2022 May; 10(10):595. PubMed ID: 35722420
[TBL] [Abstract][Full Text] [Related]
49. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
[TBL] [Abstract][Full Text] [Related]
50. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
51. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
Lei H; Xiang T; Zhu H; Hu X
Front Biosci (Landmark Ed); 2024 Mar; 29(3):129. PubMed ID: 38538256
[TBL] [Abstract][Full Text] [Related]
52. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker.
Zhao X; Liu Y; Yu S
Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1805-1816. PubMed ID: 28428004
[TBL] [Abstract][Full Text] [Related]
53. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
54. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Zhu W; Ye Z; Chen L; Liang H; Cai Q
Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
[TBL] [Abstract][Full Text] [Related]
55. Identification of an epithelial-mesenchymal transition-related lncRNA prognostic signature for patients with glioblastoma.
Yang X; Niu S; Liu J; Fang J; Wu Z; Ling S; Di G; Jiang X
Sci Rep; 2021 Dec; 11(1):23694. PubMed ID: 34880375
[TBL] [Abstract][Full Text] [Related]
56. Ferroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma.
Fang C; Liu S; Feng K; Huang C; Zhang Y; Wang J; Lin H; Wang J; Zhong C
Sci Rep; 2022 Apr; 12(1):6642. PubMed ID: 35459272
[TBL] [Abstract][Full Text] [Related]
57. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
58. Development of a lncRNA-based prognostic signature for oral squamous cell carcinoma.
Xu Z; Li X; Pan L; Tan R; Ji P; Tang H
J Oral Pathol Med; 2022 Apr; 51(4):358-368. PubMed ID: 35100473
[TBL] [Abstract][Full Text] [Related]
59. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
Wang JM; Li X; Yang P; Geng WB; Wang XY
BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
[TBL] [Abstract][Full Text] [Related]
60. Integrated analysis identifies a long non-coding RNAs-messenger RNAs signature for prediction of prognosis in hepatitis B virus-hepatocellular carcinoma patients.
Bai Z; Li H; Li C; Sheng C; Zhao X
Medicine (Baltimore); 2020 Oct; 99(40):e21503. PubMed ID: 33019382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
